The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy
about
Architecture and secondary structure of an entire HIV-1 RNA genomeThe three transfer RNAs occupying the A, P and E sites on the ribosome are involved in viral programmed -1 ribosomal frameshiftHIV-1 frameshift efficiency is primarily determined by the stability of base pairs positioned at the mRNA entrance channel of the ribosomeFrameshifting RNA pseudoknots: structure and mechanismMechanisms and implications of programmed translational frameshiftingSpecific effects of ribosome-tethered molecular chaperones on programmed -1 ribosomal frameshifting.Structural Maturation of HIV-1 Reverse Transcriptase-A Metamorphic Solution to Genomic InstabilityHIV-1 and Human PEG10 Frameshift Elements Are Functionally Distinct and Distinguished by Novel Small Molecule ModulatorsSelection of peptides interfering with a ribosomal frameshift in the human immunodeficiency virus type 1Class II transactivator (CIITA) enhances cytoplasmic processing of HIV-1 Pr55Gag.Achieving a golden mean: mechanisms by which coronaviruses ensure synthesis of the correct stoichiometric ratios of viral proteins.Structure and dynamics of the HIV-1 frameshift element RNAA loop 2 cytidine-stem 1 minor groove interaction as a positive determinant for pseudoknot-stimulated -1 ribosomal frameshiftingAdenosyl radical: reagent and catalyst in enzyme reactions.The many paths to frameshifting: kinetic modelling and analysis of the effects of different elongation steps on programmed -1 ribosomal frameshiftingA rapid, inexpensive yeast-based dual-fluorescence assay of programmed--1 ribosomal frameshifting for high-throughput screening.The highly conserved codon following the slippery sequence supports -1 frameshift efficiency at the HIV-1 frameshift site.Statistical potentials for hairpin and internal loops improve the accuracy of the predicted RNA structure.Revealing -1 programmed ribosomal frameshifting mechanisms by single-molecule techniques and computational methodsA pathophysiological approach to antiretroviral therapy.Spacer-length dependence of programmed -1 or -2 ribosomal frameshifting on a U6A heptamer supports a role for messenger RNA (mRNA) tension in frameshifting.N-Methylation as a Strategy for Enhancing the Affinity and Selectivity of RNA-binding Peptides: Application to the HIV-1 Frameshift-Stimulating RNA.The role of programmed-1 ribosomal frameshifting in coronavirus propagation.Highly conserved RNA pseudoknots at the Gag-Pol junction of HIV-1 suggest a novel mechanism of -1 ribosomal frameshiftingA review on architecture of the gag-pol ribosomal frameshifting RNA in human immunodeficiency virus: a variability survey of virus genotypes.A homogeneous cell-based bicistronic fluorescence assay for high-throughput identification of drugs that perturb viral gene recoding and read-through of nonsense stop codons.The presence of the TAR RNA structure alters the programmed -1 ribosomal frameshift efficiency of the human immunodeficiency virus type 1 (HIV-1) by modifying the rate of translation initiation.Modulation of ribosomal frameshifting frequency and its effect on the replication of Rous sarcoma virus.Model of the pathway of -1 frameshifting: Long pausing.Modulation of stop codon read-through efficiency and its effect on the replication of murine leukemia virus.Single-molecule measurements of the CCR5 mRNA unfolding pathways.Pairwise coupling analysis of helical junction hydrogen bonding interactions in luteoviral RNA pseudoknots.Interaction of the HIV-1 frameshift signal with the ribosome.
P2860
Q24498349-9E8942D6-9552-4BA3-AD8E-C7F38CABC3B0Q24565015-8BAB37B1-02D5-4798-B067-54A8B643A91BQ24628718-369B9931-310C-487D-990E-DF45A590D5A6Q24657279-B8ED7473-2287-4491-897F-B63736AF3076Q26852197-76F055D9-B02C-4C82-8D07-326970E3622CQ27940051-8E5BE5FB-3B9B-4CB4-8AF5-0856D8ED8A31Q28074527-AA1DFDA4-89E4-450C-9A25-B379C151E109Q28550143-B83A2D21-9C40-4D99-8F34-1B72A2490EB6Q33325834-5D73B3DF-9962-473C-93C4-24E03FCF9960Q33619173-E9E3A4A5-1515-49DD-97FE-3E626802A115Q33826694-C0CAF384-4774-4A08-B742-715A90A6C8E3Q33873954-FC8520C4-B3DE-4FB2-8D61-14CB0600E9F3Q33944010-E792EA85-E9CC-46B1-A0D2-4A32704D351DQ34447149-72C271CD-C42E-4C18-9E61-92FAEDF39D13Q34474113-69724347-EF3A-46BB-98F9-D93297E9CBFEQ35153545-6A419F91-AB39-4D23-A0B4-69AD9BAC835BQ35217237-C05F4DE0-80B8-49F2-8CAD-0F20DF90DE50Q35623931-CABE31D3-2BC9-4076-A138-41EDC43AD752Q35876091-16B14585-C2A8-4813-A9DA-F60AEF85E3CEQ35917460-AAC371D2-654C-4783-84F1-97EA7A2F4065Q36280734-1C02C665-2F96-49EB-A781-8A5B2485FE8BQ36482677-E2288476-B64D-4BEC-90CB-137D287670C1Q37175409-FFF104B3-F90D-4FBD-92E0-71D3AAE69B07Q37705780-CD594DFD-8B32-4D67-8F69-07758DBAE504Q38916846-6A20A3C3-C841-4016-B4B3-2C85074D7F37Q39836673-57AAD7D2-0652-4D6C-9EDA-E65B3207DC2EQ40056035-B001E537-88A9-410D-8AEB-BF5D6E858D50Q41577903-C653560C-7149-4D4F-8BA0-6D53B567CD88Q41683248-E445FB6C-836D-4347-AF33-2BFCB681C843Q41818522-8A1C3369-C8B2-4F05-B827-2737C2D253F6Q41900814-880F50E7-704F-420F-B0C0-C07D1A77CD67Q41958786-C384E5ED-EEAE-4709-B5E7-4E48F6DF09DAQ42952824-8E4AE130-9D90-4304-82A6-63E9D278CFF7
P2860
The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The human immunodeficiency vir ...... t target for antiviral therapy
@ast
The human immunodeficiency vir ...... t target for antiviral therapy
@en
The human immunodeficiency vir ...... t target for antiviral therapy
@nl
type
label
The human immunodeficiency vir ...... t target for antiviral therapy
@ast
The human immunodeficiency vir ...... t target for antiviral therapy
@en
The human immunodeficiency vir ...... t target for antiviral therapy
@nl
prefLabel
The human immunodeficiency vir ...... t target for antiviral therapy
@ast
The human immunodeficiency vir ...... t target for antiviral therapy
@en
The human immunodeficiency vir ...... t target for antiviral therapy
@nl
P2093
P2860
P3181
P1433
P1476
The human immunodeficiency vir ...... t target for antiviral therapy
@en
P2093
Annmarie L Pacchia
Joseph P Dougherty
Preetha Biswas
Stuart W Peltz
P2860
P304
P3181
P356
10.1128/JVI.78.4.2082-2087.2004
P407
P577
2004-02-01T00:00:00Z